Unnamed: 0,title,date,stock,sentiment
564738.0,"Genocea Presents Updated Long-Term Safety, Immunogenicity And Durability Data From GEN-009 Neoantigen Vaccine Phase 1/2a Trial Part A At Virtual ASCO 2020",2020-05-29 08:33:00-04:00,GNCA,positive
564739.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,GNCA,positive
564740.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2020-05-24 14:40:00-04:00,GNCA,neutral
564741.0,Genocea Announces Material Transfer And License Option Agreement With Shionogi For Proprietary GEN-003 HSV-2 Antigens; Shionogi To Pay $2M For Exclusive Option,2020-05-19 07:32:00-04:00,GNCA,positive
564742.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,GNCA,positive
564743.0,32 Stocks Moving in Thursday's Pre-Market Session,2020-05-14 07:15:00-04:00,GNCA,neutral
564744.0,Genocea Highlights Will Present Long-Term Follow-Up Data From GEN-009 Vaccine At ASCO,2020-05-13 18:09:00-04:00,GNCA,neutral
564745.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,GNCA,neutral
564746.0,20 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-05-13 07:33:00-04:00,GNCA,neutral
564747.0,30 Stocks Moving in Wednesday's Pre-Market Session,2020-05-13 07:17:00-04:00,GNCA,neutral
564748.0,"UPDATE: Genocea Sees GEN-011 Investigational New Drug Filing By End Of Q2, Sees Prelim. Clinical Data H1'21",2020-05-12 17:33:00-04:00,GNCA,neutral
564749.0,Genocea Biosciences Highlights Introduction Of GEN-011 To Improve On Current Limitations Of TIL Therapy,2020-05-12 17:32:00-04:00,GNCA,positive
564750.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,GNCA,negative
564751.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,GNCA,neutral
564752.0,Genocea Biosciences Shares Spike To Session High On Volume As Traders Circulate World Intellectual Property Organization PatentScope Doc For 'Methods and compositions for identifying tumor antigens of human lymphocytes',2020-05-07 10:03:00-04:00,GNCA,positive
564753.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,GNCA,positive
564754.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,GNCA,neutral
564755.0,100 Biggest Movers From Friday,2020-03-09 05:25:00-04:00,GNCA,neutral
564756.0,How Not To Day Trade,2020-03-06 12:44:00-05:00,GNCA,neutral
564757.0,UPDATE: Hearing Genocea Granted European Patent EP2665490 For 'Vaccines And Compositions Against Streptococcus Pneumoniae',2020-03-04 10:19:00-05:00,GNCA,positive
564758.0,"Genocea Biosciences Shares Spike To Session High, Up 9.5%, As Hearing Traders Circulate Word Of European Patent",2020-03-04 10:17:00-05:00,GNCA,positive
564759.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,GNCA,negative
564760.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,GNCA,neutral
564761.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,GNCA,negative
564762.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,GNCA,positive
564763.0,Stocks That Hit 52-Week Lows On Wednesday,2020-02-26 11:14:00-05:00,GNCA,negative
564764.0,"Genocea Biosciences Shares Spike To Session High Of Volume As Traders Circulate Chatter Of Patent for Possible Coronavirus Candidate 'In some embodiments, members of a library include polynucleotides that encode polypeptides from a virus'",2020-02-25 10:32:00-05:00,GNCA,positive
564765.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,GNCA,negative
564766.0,Genocea Biosciences Q4 EPS $(0.34) Beats $(0.39) Estimate,2020-02-13 07:37:00-05:00,GNCA,neutral
564767.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,GNCA,neutral
564768.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,GNCA,neutral
564769.0,76 Biggest Movers From Yesterday,2020-01-17 04:54:00-05:00,GNCA,neutral
564770.0,11 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-31 07:52:00-05:00,GNCA,neutral
564771.0,"Benzinga's Top Upgrades, Downgrades For November 15, 2019",2019-11-15 09:59:00-05:00,GNCA,positive
564772.0,SVB Leerink Initiates Coverage On Genocea Biosciences with Outperform Rating,2019-11-15 06:51:00-05:00,GNCA,neutral
564773.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,GNCA,positive
564774.0,Stocks That Hit 52-Week Lows On Wednesday,2019-11-13 10:50:00-05:00,GNCA,negative
564775.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,GNCA,neutral
564776.0,Genocea Presents Preclinical Research On Inhibitory Neoantigens Showing They 'Stifle Protective Anti-Tumor Immune Responses' At Society For Immunotherapy Of Cancer (SITC),2019-11-05 08:13:00-05:00,GNCA,negative
564777.0,Genocea Biosciences Filing Shows Registration For $30M Common Stock Offering,2019-10-24 09:15:00-04:00,GNCA,neutral
564778.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,GNCA,neutral
564779.0,Genocea Biosciences Q3 EPS $(0.28) Beats $(0.46) Estimate,2019-10-24 07:13:00-04:00,GNCA,neutral
564780.0,"Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More",2019-09-30 13:13:00-04:00,GNCA,positive
564781.0,Genocea Biosciences Highlights Poster Presentation at ESMO Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference,2019-09-27 08:05:00-04:00,GNCA,neutral
564782.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,GNCA,neutral
564783.0,10 Biopharmaceutical Companies Trying To Cure Cancer,2019-08-24 13:46:00-04:00,GNCA,negative
564784.0,Genocea Biosciences Q2 EPS $(0.42) Beats $(0.66) Estimate,2019-07-25 07:17:00-04:00,GNCA,neutral
564785.0,Genocea Biosciences Says it Expects to Have Enough Cash to Operate Through Q1 2021,2019-07-25 07:16:00-04:00,GNCA,neutral
564786.0,Stifel Reinstates Buy on Genocea Biosciences,2019-07-08 08:36:00-04:00,GNCA,neutral
564787.0,54 Biggest Movers From Yesterday,2019-06-27 04:54:00-04:00,GNCA,neutral
564788.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-06-26 12:17:00-04:00,GNCA,neutral
564789.0,Genocea Biosciences Shares Spike Higher On Uptick In Volume Amid Filing Showing GlaxoSmithKline Purchased ~1.86M Shares Of Co.'s Common Stock,2019-06-26 10:51:00-04:00,GNCA,positive
564790.0,54 Biggest Movers From Yesterday,2019-06-21 04:56:00-04:00,GNCA,neutral
564791.0,Genocea shares are trading lower after the company priced a 10.5 million share common stock offering at $3.50 per share.,2019-06-20 13:53:00-04:00,GNCA,positive
564792.0,35 Stocks Moving In Thursday's Mid-Day Session,2019-06-20 12:26:00-04:00,GNCA,neutral
564793.0,Mid-Morning Market Update: Markets Open Higher; Kroger Posts Upbeat Sales,2019-06-20 10:11:00-04:00,GNCA,neutral
564794.0,55 Biggest Movers From Yesterday,2019-06-20 04:55:00-04:00,GNCA,neutral
564795.0,Genocea Prices 10.5M Share Public Offering of Common Stock @$3.50/Share,2019-06-20 03:37:00-04:00,GNCA,positive
564796.0,Genocea Biosciences shares are trading lower after the company reported a 10 million shares common stock offering.,2019-06-19 15:10:00-04:00,GNCA,positive
564797.0,Mid-Afternoon Market Update: Federal Reserve Leaves Rates Unchanged; Foresight Shares Spike Higher,2019-06-19 14:56:00-04:00,GNCA,positive
564798.0,Mid-Day Market Update: Melinta Therapeutics Gains After FDA Accepts sNDA For Bacterial Pneumonia Drug; Sesen Bio Shares Drop,2019-06-19 13:08:00-04:00,GNCA,positive
564799.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-06-19 12:23:00-04:00,GNCA,neutral
564800.0,36 Stocks Moving In Wednesday's Pre-Market Session,2019-06-19 08:17:00-04:00,GNCA,neutral
564801.0,"The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut",2019-06-19 07:51:00-04:00,GNCA,positive
564802.0,A Peek Into The Markets: US Stock Futures Flat; All Eyes On Fed Decision,2019-06-19 07:36:00-04:00,GNCA,neutral
564803.0,"8 Stocks To Watch For June 19, 2019",2019-06-19 04:28:00-04:00,GNCA,neutral
564804.0,Genocea Biosciences shares are trading lower after the company reported a 10 million shares common stock offering.,2019-06-18 16:07:00-04:00,GNCA,positive
564805.0,Genocea Reports 10M Share Common Stock Offering,2019-06-18 16:05:00-04:00,GNCA,positive
564806.0,28 Stocks Moving In Monday's Pre-Market Session,2019-06-17 08:06:00-04:00,GNCA,neutral
564807.0,60 Biggest Movers From Friday,2019-06-10 06:41:00-04:00,GNCA,neutral
564808.0,3 Foolproof Strategies To Minimize Risk,2019-06-07 13:51:00-04:00,GNCA,positive
564809.0,44 Stocks Moving In Friday's Mid-Day Session,2019-06-07 12:50:00-04:00,GNCA,neutral
564810.0,66 Biggest Movers From Yesterday,2019-06-06 05:17:00-04:00,GNCA,neutral
564811.0,"Genocea Biosciences Shares Resume Trade, Spike Sharply Higher, Now Up 10.5% For Session",2019-06-05 10:44:00-04:00,GNCA,positive
564812.0,54 Biggest Movers From Yesterday,2019-06-05 06:14:00-04:00,GNCA,neutral
564813.0,"A Look At Benzinga Pro's Most-Searched Tickers For June 4, 2019",2019-06-04 17:09:00-04:00,GNCA,neutral
564814.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-06-04 12:44:00-04:00,GNCA,neutral
564815.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., June 4, 2019",2019-06-04 10:35:00-04:00,GNCA,positive
564816.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-06-04 08:07:00-04:00,GNCA,neutral
564817.0,66 Biggest Movers From Yesterday,2019-06-04 05:19:00-04:00,GNCA,neutral
564818.0,Mid-Afternoon Market Update: NASDAQ Down 1.5%; Genocea Biosciences Shares Spike Higher,2019-06-03 14:38:00-04:00,GNCA,positive
564819.0,"A Look At Benzinga Pro's Most-Searched Tickers For June 3, 2019",2019-06-03 13:41:00-04:00,GNCA,neutral
564820.0,Genocea Biosciences Rallies 50% On ASCO Presentation,2019-06-03 12:47:00-04:00,GNCA,neutral
564821.0,51 Stocks Moving In Monday's Mid-Day Session,2019-06-03 12:46:00-04:00,GNCA,neutral
564822.0,Mid-Day Market Update: El Paso Electric Rises On Acquisition News; DelMar Pharmaceuticals Shares Plummet,2019-06-03 12:16:00-04:00,GNCA,positive
564823.0,Mid-Morning Market Update: Markets Mixed; Infineon To Buy Cypress Semiconductor For $10B,2019-06-03 10:34:00-04:00,GNCA,neutral
564824.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Mon., June 3, 2019",2019-06-03 10:28:00-04:00,GNCA,positive
564825.0,30 Stocks Moving In Monday's Pre-Market Session,2019-06-03 08:12:00-04:00,GNCA,neutral
564826.0,"Genocea Biosciences shares are trading higher after the company presented results from its ongoing Phase 1/2a trial for GEN-009, the company's lead neoantigen vaccine candidate, at ASCO 2019.",2019-06-03 07:50:00-04:00,GNCA,positive
564827.0,Genocea Biosciences Announce Clinical Results From its Phase 1/2a Trial for GEN-009,2019-06-03 07:07:00-04:00,GNCA,neutral
564828.0,64 Biggest Movers From Friday,2019-06-03 06:12:00-04:00,GNCA,neutral
564829.0,Mid-Afternoon Market Update: Dow Falls Over 300 Points; Williams-Sonoma Shares Climb On Upbeat Earnings,2019-05-31 14:41:00-04:00,GNCA,positive
564830.0,45 Stocks Moving In Friday's Mid-Day Session,2019-05-31 12:33:00-04:00,GNCA,neutral
564831.0,Mid-Day Market Update: Crude Oil Down 2.9%; Stellar Biotechnologies Shares Spike Higher,2019-05-31 12:09:00-04:00,GNCA,negative
564832.0,Low-Float Du Jour: Genocea Biosciences,2019-05-31 11:48:00-04:00,GNCA,neutral
564833.0,Mid-Morning Market Update: Markets Open Lower; Big Lots Earnings Top Expectations,2019-05-31 10:31:00-04:00,GNCA,negative
564834.0,"Genocea Biosciences Shares Resume Trade, Up 57.3%",2019-05-31 10:28:00-04:00,GNCA,positive
564835.0,"Genocea Biosciences Shares Halted On Second Circuit Breaker, Up 57.3%",2019-05-31 10:05:00-04:00,GNCA,positive
564836.0,"Genocea Biosciences Shares Resume Trade, Continue Higher, Now Up 44.5%",2019-05-31 10:03:00-04:00,GNCA,positive
564837.0,Genocea Biosciences Shares Halted On Circuit Breaker,2019-05-31 09:53:00-04:00,GNCA,positive
564838.0,Genocea's GEN-009 Clinical Results Presentation Selected By ASCO's Journal Of Clinical Oncology As A Top 10 Featured Immuno-oncology Abstract,2019-05-31 08:03:00-04:00,GNCA,positive
564839.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,GNCA,neutral
564840.0,"Genocea Biosciences 8-K Shows News Of 1-For-8 Reverse Stock Split Effective May 22, 2019",2019-05-21 08:19:00-04:00,GNCA,positive
564841.0,"Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward",2019-05-16 12:30:00-04:00,GNCA,negative
564842.0,Genocea Reports Interim Immunogenicity Data From GEN-009 Neoantigen Vaccine Phase 1/2a Trial: 'Post-vaccination immune responses detected to 93% of vaccine neoantigens in first three patients analyzed',2019-05-16 08:07:00-04:00,GNCA,positive
564843.0,Genocea Biosciences Q1 EPS $(0.15) Misses $(0.09) Estimate,2019-04-30 08:53:00-04:00,GNCA,negative
564844.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,GNCA,positive
564845.0,Genocea Biosciences shares are trading higher after the company presented data supporting the utility of its ATLAS platform at the AACR 2019 event.,2019-04-03 09:25:00-04:00,GNCA,positive
564846.0,"Genocea Biosciences shares down sharply, well below the $1 level, following slightly worse-than-expected Q4 results and news of a new CFO, Diantha Duvall",2019-02-28 09:27:00-05:00,GNCA,positive
564847.0,Genocea Biosciences Q4 EPS $(0.13) Misses $(0.12) Estimate,2019-02-28 08:34:00-05:00,GNCA,negative
564848.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,GNCA,positive
564849.0,66 Biggest Movers From Yesterday,2019-01-03 05:00:00-05:00,GNCA,neutral
564850.0,45 Stocks Moving In Wednesday's Mid-Day Session,2019-01-02 12:21:00-05:00,GNCA,neutral
564851.0,"Genocea Biosciences shares are trading higher after the company announced it dosed its first patients and completed enrollment in Part A of Phase 1/2a in the clinical trial for the neoantigen vaccine candidate, GEN-009.",2019-01-02 09:18:00-05:00,GNCA,positive
564852.0,Genocea Biosciences Doses First Patients And Completes Enrollment In Part A Of Phase 1/2a Clinical Trial For Neoantigen Vaccine Candidate GEN-009,2019-01-02 08:12:00-05:00,GNCA,neutral
564853.0,"The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO",2018-12-28 07:29:00-05:00,GNCA,neutral
564854.0,"The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede",2018-12-27 07:51:00-05:00,GNCA,neutral
564855.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,GNCA,neutral
564856.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,GNCA,positive
564857.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,GNCA,negative
564858.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,GNCA,positive
564859.0,Genocea Biosciences Q3 EPS $(0.09) Beats $(0.11) Estimate,2018-11-01 08:59:00-04:00,GNCA,neutral
564860.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,GNCA,negative
564861.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,GNCA,negative
564862.0,"The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares",2018-09-18 08:44:00-04:00,GNCA,positive
564863.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,GNCA,negative
564864.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,GNCA,negative
564865.0,"Stocks Which Set New 52-Week Low Yesterday, September 12th",2018-09-13 10:19:00-04:00,GNCA,negative
564866.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,GNCA,neutral
564867.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,GNCA,negative
564868.0,"The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt",2018-09-12 08:26:00-04:00,GNCA,positive
564869.0,"Stocks Which Set New 52-Week Low Yesterday, August 1st",2018-08-02 11:07:00-04:00,GNCA,negative
564870.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,GNCA,positive
564871.0,Genocea Biosciences Q2 EPS $(0.05) Beats $(0.13) Estimate,2018-08-02 08:07:00-04:00,GNCA,neutral
564872.0,"Stocks Which Set New 52-Week Low Yesterday, July 31",2018-08-01 12:16:00-04:00,GNCA,negative
564873.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,GNCA,negative
564874.0,"Stocks Which Set New 52-Week Low Yesterday, July 30th",2018-07-31 09:25:00-04:00,GNCA,negative
564875.0,"Stocks Which Set New 52-Week Low Yesterday, July 25th",2018-07-26 11:19:00-04:00,GNCA,negative
564876.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,GNCA,negative
564877.0,"Stocks Which Set New 52-Week Lows Yesterday, July 24th:",2018-07-25 12:17:00-04:00,GNCA,negative
564878.0,"Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile",2018-07-25 08:41:00-04:00,GNCA,positive
564879.0,Stocks Which Set New 52-Week Lows Yesterday:,2018-07-24 12:10:00-04:00,GNCA,negative
564880.0,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",2018-07-24 08:53:00-04:00,GNCA,positive
564881.0,"Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut",2018-07-19 09:14:00-04:00,GNCA,neutral
564882.0,"Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4",2018-07-17 08:37:00-04:00,GNCA,neutral
564883.0,Genocea Biosciences S-3 Shows Registration For $200M Mixed Securities Shelf Offering,2018-05-21 17:26:00-04:00,GNCA,positive
564884.0,Genocea Biosciences Q1 EPS $(0.21) Misses $(0.15) Estimate,2018-05-10 07:59:00-04:00,GNCA,negative
564885.0,Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009,2018-04-30 08:14:00-04:00,GNCA,negative
564886.0,Genocea Biosciences To Offer Data On ATLAS Platform At AACR: Showed In Silico Methods Missed Most Empirically Confirmed Neoantigens,2018-04-18 09:04:00-04:00,GNCA,negative
564887.0,56 Biggest Movers From Yesterday,2018-03-09 04:51:00-05:00,GNCA,neutral
564888.0,HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies,2018-03-08 15:23:00-05:00,GNCA,neutral
564889.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-03-08 12:31:00-05:00,GNCA,neutral
564890.0,"Benzinga's Top Upgrades, Downgrades For March 8, 2018",2018-03-08 09:13:00-05:00,GNCA,positive
564891.0,"H.C. Wainwright Initiates Coverage On Genocea Biosciences with Buy Rating, Announces $5.00 Price Target",2018-03-08 07:12:00-05:00,GNCA,neutral
564892.0,"Benzinga Pro's Top 10 Most-Searched Tickers On Wed., Mar. 7",2018-03-07 12:53:00-05:00,GNCA,positive
564893.0,"Benzinga Pro's Top 10 Most-Searched Tickers On Tues., Mar. 6",2018-03-06 12:59:00-05:00,GNCA,positive
564894.0,Genocea Biosciences Shares Up 15.2% After Cantor Fitzgerald Earlier Initiated Stock At Overweight,2018-03-06 12:41:00-05:00,GNCA,negative
564895.0,"Cantor Fitzgerald Initiates Coverage On Genocea Biosciences with Overweight Rating, Announces $5.00 Price Target",2018-03-06 07:07:00-05:00,GNCA,negative
564896.0,Genocea Biosciences Reports Q4 Net Loss $10.7M vs Loss Of $16M In Same Qtr. Last Year,2018-02-15 08:03:00-05:00,GNCA,negative
564897.0,"Benzinga's Top Upgrades, Downgrades For February 12, 2018",2018-02-12 09:33:00-05:00,GNCA,positive
564898.0,"Baird Initiates Coverage On Genocea Biosciences with Outperform Rating, Announces $3.00 Price Target",2018-02-12 06:46:00-05:00,GNCA,neutral
564899.0,Needham Upgrades Genocea Biosciences to Buy,2018-02-06 08:39:00-05:00,GNCA,neutral
564900.0,Genocea Biosciences 13G Filing From Vivo Opportunity Shows New 9.99% Stake,2018-01-26 16:41:00-05:00,GNCA,positive
564901.0,New Enterprise Associates Reports 39.7% Stake In Genocea Biosciences Inc As Of Jan 17 -13D,2018-01-26 14:45:00-05:00,GNCA,neutral
564902.0,Genocea Biosciences Prices Offering Of ~53.4M Common Shares Accompanying Class A Warrants To Buy Up To ~26.68M Shares At $1/Share For Gross Proceeds $53.4M,2018-01-17 08:41:00-05:00,GNCA,positive
564903.0,"Genocea Biosciences Reports Offering Of Common Stock, Class A Warrants, Series A Convertible Preferred Stock",2018-01-16 16:05:00-05:00,GNCA,neutral
564904.0,Genocea Offers New Results For ATLAS Antigen ID Platform: 'ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types',2017-11-07 08:48:00-05:00,GNCA,negative
564905.0,Genocia Reports Q3 EPS $(0.59) vs. $(0.53) Est.,2017-11-02 08:03:00-04:00,GNCA,neutral
564906.0,Mid-Afternoon Market Update: Ascena Retail Climbs Following Strong Earnings; Axovant Sciences Shares Plunge,2017-09-26 14:31:00-04:00,GNCA,positive
564907.0,What The GEN-003 News Means For Genocea,2017-09-26 13:31:00-04:00,GNCA,neutral
564908.0,15 Biggest Mid-Day Losers For Tuesday,2017-09-26 13:04:00-04:00,GNCA,negative
564909.0,Mid-Day Market Update: Crude Oil Down Over 1%; Moleculin Biotech Shares Spike Higher,2017-09-26 12:03:00-04:00,GNCA,negative
564910.0,Mid-Morning Market Update: Markets Open Higher; FactSet Research Profit Beats Views,2017-09-26 10:13:00-04:00,GNCA,positive
564911.0,Genocea Shares Down ~63% Just Before Market Open,2017-09-26 09:29:00-04:00,GNCA,positive
564912.0,"Street Abandons Genocea On Strategic Shift, CEO Says Oncology Focus Wasn't Sudden",2017-09-26 09:01:00-04:00,GNCA,negative
564913.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-09-26 08:10:00-04:00,GNCA,neutral
564914.0,Stifel Nicolaus Downgrades Genocea Biosciences to Hold,2017-09-26 06:46:00-04:00,GNCA,neutral
564915.0,"Genocea CEO Clark On Reviewing Of Strategic Alternatives For GEN-003, Tells Benzinga, '...we seek the right partner to move the program forward.'",2017-09-25 18:04:00-04:00,GNCA,neutral
564916.0,"Genocea CEO Clark On GEN-003 Decision, Tells Benzinga, 'The significant financial resources required to advance GEN-003 into a large and long Phase 3 program are beyond Genocea alone.'",2017-09-25 18:04:00-04:00,GNCA,positive
564917.0,"Genocea CEO Chip Clark Elaborates On Decision To Shift Toward Immuno-oncology, Highlights To Benzinga, '...the great potential we see for our ATLAS platform to be superior to others' approaches for neoantigen selection'",2017-09-25 18:04:00-04:00,GNCA,positive
564918.0,Genocea Shares Fall ~35% Shortly After Resumption,2017-09-25 17:01:00-04:00,GNCA,positive
564919.0,Genocea Shares Open For Trade Following Halt; Not Yet Seeing Any Price Action,2017-09-25 17:00:00-04:00,GNCA,positive
564920.0,Genocea Shares To Resume Trade At 5 p.m. EDT,2017-09-25 16:35:00-04:00,GNCA,positive
564921.0,"UPDATE: Genocea Sees Existing Cash, Cash Equivalents Sufficient To Support Operating, Capital Expense Requirements Into Middle Of '18",2017-09-25 16:35:00-04:00,GNCA,positive
564922.0,"UPDATE: Genocea Sees Annualized Savings Of ~$6.5M In Personnel-Related Costs, Sees 1-Time Severance Charge Of ~$1.1M In Q3'17",2017-09-25 16:34:00-04:00,GNCA,neutral
564923.0,"UPDATE: Genocea Says Is Ceasing GEN-003 Spending, Activities, Is Reducing Workforce By ~40%",2017-09-25 16:33:00-04:00,GNCA,neutral
564924.0,UPDATE: Genocea Says 'plans to initiate a Phase 1 clinical trial for GEN-009 in a range of tumor types in 1H'18 and expects to report initial immunogenicity data in the 1H'19',2017-09-25 16:33:00-04:00,GNCA,negative
564925.0,UPDATE: Genocea Reports Corporate Restructuring,2017-09-25 16:31:00-04:00,GNCA,neutral
564926.0,UPDATE: Genocea Announces Will Explore Strategic Alternatives For GEN-003,2017-09-25 16:31:00-04:00,GNCA,neutral
564927.0,"Genocea Reports Strategic Shift To Immuno-oncology, Development Of Neoantigen Cancer Vaccines",2017-09-25 16:31:00-04:00,GNCA,negative
564928.0,Genocea Shares Halted News Pending,2017-09-25 16:25:00-04:00,GNCA,positive
564929.0,Genocea Biosciences Reports Q2 EPS $(0.54) vs $(0.47) Est.,2017-08-09 08:20:00-04:00,GNCA,neutral
564930.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-07-25 08:24:00-04:00,GNCA,neutral
564931.0,Genocea Shares Spike ~$0.30 Higher Over Last Min. As Traders Circulating Report Of Cowen Research Note Highlighting Belief GEN-003 Has Greater Than $700M Peak Sales Potential,2017-07-24 14:24:00-04:00,GNCA,positive
564932.0,Hearing Needham Upgrades Genocea From Hold To Buy,2017-07-24 13:48:00-04:00,GNCA,neutral
564933.0,18 Biggest Mid-Day Gainers For Monday,2017-07-24 12:24:00-04:00,GNCA,neutral
564934.0,Genocea BeioSciences Shares Up 11.7% Pre-Market On Report Of 'Positive' Phase 2b Data for GEN-003,2017-07-24 08:24:00-04:00,GNCA,positive
564935.0,25 Stocks Moving In Monday's Pre-Market Session,2017-07-24 08:22:00-04:00,GNCA,neutral
564936.0,Genocea Reports 'Positive' Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes,2017-07-24 07:13:00-04:00,GNCA,neutral
564937.0,"Genocea Biosciences Q1 EPS $(0.48) vs $(0.54) Est, No Sales",2017-05-04 08:16:00-04:00,GNCA,negative
564938.0,Hearing Unconfirmed Market Chatter of $12-$15 Bid for Genocea,2017-03-08 09:49:00-05:00,GNCA,negative
564939.0,Needham Downgrades Genocea Biosciences To Hold,2017-02-17 09:22:00-05:00,GNCA,neutral
564940.0,Genocea Biosciences Reports Q4 Net Loss $16M vs Net Loss $10.3M in Same Qtr. Last Year,2017-02-16 07:32:00-05:00,GNCA,negative
564941.0,15 Biggest Mid-Day Gainers For Thursday,2017-01-05 12:38:00-05:00,GNCA,neutral
564942.0,"Genocea Biosciences Higher Off Positive Clinical Data, Favorable Analyst Comments",2017-01-05 12:15:00-05:00,GNCA,positive
564943.0,"Cowen Out Positive On Genocea Biosciences, Says Co. Is Significantly Undervalued",2017-01-05 10:17:00-05:00,GNCA,positive
564944.0,Genocea Shares Bounce from Session Lows as Traders Passing Around Word of Increased Price Target from $13 to $17 at Piper Jaffray,2017-01-05 10:05:00-05:00,GNCA,positive
564945.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-01-05 08:23:00-05:00,GNCA,neutral
564946.0,Genocea +21% Premarket @$5.49 After Announcing Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial,2017-01-05 06:39:00-05:00,GNCA,positive
564947.0,Genocea Announces 'Positive' 6-Month Results from GEN-003 Phase 2b Clinical Trial,2017-01-05 06:31:00-05:00,GNCA,neutral
564948.0,"Genocea Reports ATLAS 'discovers neoantigens, through functional T cell responses, which were not identified by predictive algorithms'",2016-11-11 07:04:00-05:00,GNCA,neutral
564949.0,Genocea Biosciences Reports Q3 EPS $(0.45) vs. Est. $(0.44),2016-11-03 07:35:00-04:00,GNCA,neutral
564950.0,"Genocea Q3 EPS $(0.45) vs $(0.44) Est, No Revenue",2016-11-03 07:34:00-04:00,GNCA,negative
564951.0,20 Biggest Mid-Day Gainers For Friday,2016-10-28 12:24:00-04:00,GNCA,neutral
564952.0,18 Stocks Moving In Friday's Pre-Market Session,2016-10-28 08:37:00-04:00,GNCA,neutral
564953.0,"Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003; Says Data Provide Strong Evidence of Clear, Robust T, B Cell Immune Responses",2016-10-28 07:49:00-04:00,GNCA,positive
564954.0,15 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-26 07:02:00-04:00,GNCA,neutral
564955.0,"18 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-30 10:59:00-04:00,GNCA,neutral
564956.0,12 Biggest Mid-Day Losers For Thursday,2016-09-29 13:10:00-04:00,GNCA,negative
564957.0,"UPADTE: Needham Says 'We continue to view GEN-003 favorably', Expects Moderate Improvements Over Current HSV2 Standard Of Care In Patients W/ More Active Disease",2016-09-29 10:30:00-04:00,GNCA,positive
564958.0,"Needham Positive On Genocea, Reiterating Buy, PT $15",2016-09-29 10:28:00-04:00,GNCA,positive
564959.0,"PiperJaffray Maintains Overweight on Genocea Biosciences, Raises PT to $12.00, Expects GEN-003 Approval In 20200 And US Launch In 2021 W/ Sales Exceeding $1B By 2025",2016-09-29 10:11:00-04:00,GNCA,positive
564960.0,15 Stocks Moving In Thursday's Pre-Market Session,2016-09-29 08:20:00-04:00,GNCA,neutral
564961.0,Genocea Shares to Resume Trade at 8 a.m. EDT,2016-09-29 07:37:00-04:00,GNCA,positive
564962.0,"Genocea Reports Phase 2b Trial of GEN-003 for Genital Herpes Met Primary Endpoint, Dose is Confirmed for Subsequent Trials",2016-09-29 07:31:00-04:00,GNCA,neutral
564963.0,Genecea Shares Halted News Pending,2016-09-29 07:26:00-04:00,GNCA,positive
564964.0,"Bio Pharma Companies Expected To Report Data By Friday Sept. 30 Include Genocea Biosciences, SCYNEXIS, Threshold Pharmaceuticals, Arbutus Biopharma, Cytori Therapeutics, Esperion Therapeutics, Mesoblast, Marinus Pharmaceuticals, & Syndax Pharmaceuticals",2016-09-26 17:17:00-04:00,GNCA,neutral
564965.0,Genocea Reports Q2 EPS $(0.39) vs. $(0.44),2016-08-04 07:54:00-04:00,GNCA,neutral
564966.0,Genocea Reports Q1 Net Loss $9.8M vs $12.1M in Same Qtr. Last Year,2016-05-05 08:26:00-04:00,GNCA,negative
564967.0,10 Stocks Moving In Friday's Pre-Market Session,2016-04-01 08:22:00-04:00,GNCA,neutral
564968.0,Genocea Shares Spike to Premarket High of $7.94,2016-04-01 07:45:00-04:00,GNCA,positive
564969.0,Must Watch Stocks for Today,2016-04-01 04:52:00-04:00,GNCA,neutral
564970.0,10 Stocks Moving In Today's After-Hours Session,2016-03-31 16:59:00-04:00,GNCA,neutral
564971.0,Adam Feuerstein Tweets:@IraBidermanDDS The GEN-003 vs placebo lesion reduction data disclosed by $GNCA today (slides 9 & 10) look terrible. No difference.,2016-03-31 16:46:00-04:00,GNCA,negative
564972.0,"Cowen Cautions the 'Market Exclusivity of Genocea's Vaccines is Largely Dependent on their Patents, Which Could be Subject to Challenge'",2016-03-31 14:15:00-04:00,GNCA,positive
564973.0,"Genocea Shares Moving Higher; Cowen Reiterates Outperform, $40 PT",2016-03-31 14:11:00-04:00,GNCA,positive
564974.0,Genocea Biosciences Spikes 30% After Positive Data From Phase 2 Trial,2016-03-31 10:11:00-04:00,GNCA,positive
564975.0,"Genocea Biosciences Reports GEN-003 Showed Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post Dosing",2016-03-31 07:02:00-04:00,GNCA,neutral
564976.0,Genocea Reports Q4 EPS $(0.37) vs. Est. $(0.40),2016-02-11 07:38:00-05:00,GNCA,neutral
564977.0,"Genocea Starts Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003; Top-Line Data Expected Mid-2016",2016-01-29 08:01:00-05:00,GNCA,neutral
564978.0,Benzinga's Top Initiations,2015-12-17 10:02:00-05:00,GNCA,positive
564979.0,"UBS Initiates Coverage on Genocea Biosciences at Buy, Announces $15.00 PT",2015-12-17 08:19:00-05:00,GNCA,neutral
564980.0,Genocea Presents Positive Findings from ATLASTM Immuno-Oncology Research Collaboration at 2015 SITC Annual Meeting,2015-11-04 07:06:00-05:00,GNCA,positive
564981.0,Mid-Afternoon Market Update: Genocea Biosciences Declines Following Announcement of Suspension of Development of GEN-004; PMC-Sierra Shares Surge,2015-10-19 15:22:00-04:00,GNCA,positive
564982.0,Mid-Day Market Update: Weight Watchers Jumps On Oprah Stake; Great Lakes Dredge & Dock Shares Drop,2015-10-19 12:34:00-04:00,GNCA,positive
564983.0,Stocks Hitting 52-Week Lows,2015-10-19 10:15:00-04:00,GNCA,negative
564984.0,Mid-Morning Market Update: Markets Mixed; Morgan Stanley Profit Misses Views,2015-10-19 10:04:00-04:00,GNCA,positive
564985.0,Morning Market Losers,2015-10-19 09:50:00-04:00,GNCA,negative
564986.0,Benzinga's Top #PreMarket Losers,2015-10-19 08:24:00-04:00,GNCA,negative
564987.0,Genocea Biosciences -34% Premarket Following Announcement of Suspension of Develpment of GEN-004,2015-10-19 07:37:00-04:00,GNCA,neutral
564988.0,Genocea Biosciences to Resume Trading @7:30 AM ET,2015-10-19 07:12:00-04:00,GNCA,neutral
564989.0,UPDATE: Genocea Suspends Development Pending Further Review of Data and Potential Paths Forward,2015-10-19 07:03:00-04:00,GNCA,neutral
564990.0,"UPDATE: Genocea Biosciences Says Consistent Reductions vs Placebo in Rate, Density of Colonization; Not Statistically Significant",2015-10-19 07:02:00-04:00,GNCA,negative
564991.0,Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-004,2015-10-19 07:00:00-04:00,GNCA,neutral
564992.0,Genocea Biosciences Halted; Pending News,2015-10-19 06:57:00-04:00,GNCA,neutral
564993.0,Genocea Biosiences Says Phase 2 Study Results Positive For Multiple Endpoints,2015-10-07 07:04:00-04:00,GNCA,positive
564994.0,Genocea Reports Q2 EPS $(0.43) vs. Est. $(0.51),2015-08-06 08:21:00-04:00,GNCA,neutral
564995.0,Genocea Biosciences Prices $50M Offering At $13/Share,2015-07-30 08:06:00-04:00,GNCA,neutral
564996.0,Benzinga's Volume Movers,2015-05-20 10:23:00-04:00,GNCA,neutral
564997.0,Morning Market Gainers,2015-05-20 09:43:00-04:00,GNCA,neutral
564998.0,Genocea Reports Top-Line Phase 2 Data for GEN-003: Showed Highlty Statistcally Significant 55% Reduction in Viral Shedding Rate with Best Dose,2015-05-20 07:00:00-04:00,GNCA,positive
564999.0,Genocea Biosciences Files $250M Mixed Shelf,2015-05-08 12:03:00-04:00,GNCA,neutral
565000.0,Genocea Completes Enrollment in Phase 2a Human Challenge Study of GEN-004 for the Prevention of Infection by Pneumococcus,2015-04-22 08:05:00-04:00,GNCA,positive
565001.0,Genocea Finishes Enrollment in Phase 2a Human Challenge Study of GEN-004 for the Prevention of Infection by Pneumococcus,2015-04-22 08:01:00-04:00,GNCA,positive
565002.0,Benzinga's Top Initiations,2015-04-21 09:36:00-04:00,GNCA,positive
565003.0,FBR Capital Initiates Genocea Biosciences With Outperform,2015-04-21 08:28:00-04:00,GNCA,neutral
565004.0,"FBR Capital Initiates Coverage on Genocea Biosciences at Outperform, Announces $20.00 PT",2015-04-21 06:08:00-04:00,GNCA,neutral
565005.0,"Piper Jaffray Initiates Coverage on Genocea Biosciences at Overweight, Announces $14.00 PT",2015-03-18 06:03:00-04:00,GNCA,negative
565006.0,"Genocea Biosciences Director Hoffman Buys 700,000 Shares @$8.25/Share -Form 4",2015-03-17 16:52:00-04:00,GNCA,positive
565007.0,Genocea Biosciences Prices $45M Offering At $8.25/Share,2015-03-12 08:54:00-04:00,GNCA,neutral
565008.0,Genocea Reports Fourth Quarter Q4 EPS $(0.66),2015-02-12 08:12:00-05:00,GNCA,neutral
565009.0,Genocea Biosciens Says It Expects Topline Phase 2 Data in Late Q2,2015-01-07 08:31:00-05:00,GNCA,neutral
565010.0,Genoca Appoints Eric Hoffman As Chief Business Officer,2014-12-15 10:57:00-05:00,GNCA,neutral
565011.0,Genocea Biosciences Enters Loan Agreement With Hercules Technology Growth Capital For Up To $27M,2014-11-21 08:31:00-05:00,GNCA,positive
565012.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,GNCA,neutral
565013.0,UPDATE: Stifel Reiterates On Genocea Biosciences On Attractive Risk/Reward,2014-11-07 09:11:00-05:00,GNCA,positive
565014.0,"Stifel Nicolaus Maintains Buy on Genocea, Lowers PT to $24.00",2014-11-07 07:41:00-05:00,GNCA,negative
565015.0,Genocea Reports Q3 EPS of $(0.53) vs $(0.51) Est,2014-11-06 08:07:00-05:00,GNCA,neutral
565016.0,Genocea Reports Closing of Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek,2014-10-08 09:00:00-04:00,GNCA,neutral
565017.0,Genocea Announces $1.2M Grant ,2014-09-23 08:03:00-04:00,GNCA,positive
565018.0,"Genocea Announces Commencement of Phase 2a Trial for GEN-004, Says Expects to Enroll ~90 Patients",2014-09-11 14:03:00-04:00,GNCA,neutral
565019.0,Genocea Reports Q2 EPS of $(0.41) vs $(0.45) Est,2014-08-06 08:08:00-04:00,GNCA,neutral
565020.0,Genocea Announces Start of Phase 2 Dosing,2014-07-21 08:05:00-04:00,GNCA,neutral
565021.0,Genocea Biosciences Announces Has Elected Not to Pursue Offering,2014-07-16 11:30:00-04:00,GNCA,neutral
565022.0,Amended S-1 Filing from Genocea Biosciences Shows Will Sell 3.4M Shares Through Offering,2014-07-14 08:08:00-04:00,GNCA,positive
565023.0,Genocea Biosciences Reports Commencement of Offering of 3.4M Shares,2014-07-14 07:30:00-04:00,GNCA,positive
565024.0,Genocea Announces Positive Top Line Results for Phase 1/2a Trail,2014-07-01 08:02:00-04:00,GNCA,positive
565025.0,Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004 ,2014-06-23 08:02:00-04:00,GNCA,positive
565026.0,Genocea Appoints Jonathan Poole as CFO,2014-04-07 09:01:00-04:00,GNCA,neutral
565027.0,"UPDATE: Genocea Says Patients Saw 72% Reduction in Lesion Days After Six Months, Expecting to Announce 12-Month Data in Mid 2014",2014-03-24 15:03:00-04:00,GNCA,neutral
565028.0,Genocea's Therapeutic Vaccine For Herpes Simplex-2 Infection Shows Highly Significant Reductions In Clinical Symptoms at 6 Months,2014-03-24 15:00:00-04:00,GNCA,positive
565029.0,"Mid-Day Gainers Mar. 7, 2014: SKUL, SMSI, DLIA, BIG, CVM, KFY, GTAT",2014-03-07 11:26:00-05:00,GNCA,positive
565030.0,"Needham Initiates Coverage on Genocea at Buy, Announces $22.00 PT",2014-03-05 07:52:00-05:00,GNCA,neutral
565031.0,"Stifel Nicolaus Initiates Coverage on Genocea at Buy, Announces $25.00 PT",2014-03-03 08:50:00-05:00,GNCA,neutral
565032.0,"Citigroup Initiates Coverage on Genocea at Buy, Announces $25.00 PT",2014-03-03 08:08:00-05:00,GNCA,neutral
565033.0,Shares of Genocea Biosciences Open at $11.70/Share After Pricing at $12,2014-02-05 11:21:00-05:00,GNCA,positive
565034.0,Waiting on IPO Opens for:,2014-02-05 10:25:00-05:00,GNCA,neutral
565035.0,Genocea Biosciences Announces Pricing of Initial Public Offering at $12 per Share,2014-02-05 09:05:00-05:00,GNCA,positive
565036.0,Genocea Files Up to $75M IPO ,2013-12-23 14:27:00-05:00,GNCA,neutral
